Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Analyzing a biotech 10-K stuffed with immunology diagrams is challenging enough; doing it for Q32 Bio Inc. (QTTB), with its dual adaptive- and innate-immunity programs, can feel overwhelming. Trial data for bempikibart and ADX-097, cash-runway math, and dilution clauses are buried across multiple SEC documents.
Our platform turns that complexity into clarity. Stock Titan’s AI delivers line-by-line explanations, transforming Q32 Bio annual report 10-K simplified summaries, pinpointing R&D spend, and flagging risk-factor changes. Need the latest Q32 Bio quarterly earnings report 10-Q filing or want Q32 Bio 8-K material events explained? They appear here moments after hitting EDGAR—complete with section-level highlights you can skim in minutes.
Stay ahead of management moves with Q32 Bio insider trading Form 4 transactions. Our feed shows Q32 Bio Form 4 insider transactions real-time, alerting you to option exercises or sales that may precede clinical milestones. You’ll also find:
- Q32 Bio proxy statement executive compensation parsed into easy tables
- Cash-burn trends and share-issuance details inside every 10-Q
- Quick-read notes that make understanding Q32 Bio SEC documents with AI effortless
Whether you’re dissecting a financing 8-K or searching for Q32 Bio executive stock transactions Form 4, our AI-driven dashboard surfaces the facts that matter. Use the built-in comparison tool for Q32 Bio earnings report filing analysis across quarters, monitor trial updates without wading through pages of technical jargon, and make informed decisions faster.
Q32 Bio (QTTB) reported third‑quarter 2025 results showing sharply lower operating spend and a narrower loss, alongside a reduced cash balance and an equity deficit. Cash and cash equivalents were $49.0 million as of September 30, 2025, down from $78.0 million at year‑end. Total assets were $57.8 million against total liabilities of $76.2 million, resulting in stockholders’ equity (deficit) of $(18.4) million.
Quarterly net loss was $7.4 million versus $17.6 million a year ago as research and development fell to $3.6 million from $14.3 million, with general and administrative at $4.0 million. For the nine months, net loss totaled $27.9 million, and operating cash outflow was $27.4 million. The company expects its cash to fund operations for at least one year from the financial statement issuance date. Management executed a February 2025 restructuring to prioritize bempikibart in AA, discontinued the Phase 2 ADX‑097 renal basket trial, and recorded $0.9 million of severance costs. The company also completed the sale of its 10% OXB (US) LLC interest for $2.5 million and eliminated the related CVR liability by quarter end.
Q32 Bio Inc. reported that it announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to an Item 2.02 current report.
The information in the report, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Q32 Bio’s common stock trades on the Nasdaq Global Market under the symbol QTTB.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.
Q32 Bio (QTTB) reported a director’s stock option grant on a Form 4. On 10/23/2025, the director acquired 53,521 stock options (Code A) with an exercise price of $2.80 per share, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual stockholder meeting, contingent on continued service. Following this transaction, the director beneficially owns 53,521 derivative securities, held directly. The price of the derivative security was listed as $0.00.
Q32 Bio (QTTB) reported a director stock option grant. On 10/23/2025, the reporting person received a stock option for 53,521 shares at an exercise price of $2.80 per share. Following the transaction, 53,521 derivative securities were beneficially owned directly.
The option vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service, and expires on 10/22/2035. The filing lists the grant as an acquisition.
Q32 Bio Inc. (QTTB) reported a director stock option grant on a Form 4. The filing lists a stock option (right to buy) for 53,521 shares at an exercise price of $2.80, dated 10/23/2025, with an expiration on 10/22/2035. The option acquisition is recorded at $0.00 for the derivative security.
Vesting occurs in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service. The ownership form is listed as Direct. A footnote states the reporting person is obligated, pursuant to an agreement, to transfer any securities or economic benefits from such awards to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure they are provided to OrbiMed Private Investments VII, LP.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. On 10/23/2025, the director was awarded 53,521 stock options at an exercise price of $2.80 per share. The options expire on 10/22/2035 and will vest in full on the earlier of 10/23/2026 or the company’s next annual stockholder meeting, subject to continued service. Following the grant, the director beneficially owns 53,521 derivative securities directly.
Q32 Bio (QTTB) reported a director equity grant on a Form 4. On 10/23/2025, the director was granted a stock option for 53,521 shares at an exercise price of $2.8 per share, expiring on 10/22/2035. The option vests in full upon the earlier of October 23, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continued service. Following the grant, 53,521 derivative securities were beneficially owned in direct form.
The filing notes that proceeds of any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and the Reporting Person disclaims ownership except to the extent of any pecuniary interest.
Q32 Bio (QTTB) reported a Form 4 for a director reflecting a grant of stock options. The filing lists a Stock Option (Right to Buy) for 53,521 shares at an exercise price of $2.8 per share on 10/23/2025.
These options vest in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the reporting person’s continued service on the vesting date. The option carries an expiration date of 10/22/2035 and is held directly. The grant price for the derivative security is shown as $0.00, consistent with option awards.
Q32 Bio Inc. (QTTB) reported an insider equity award on a Form 4. A director received a stock option grant covering 53,521 shares on 10/23/2025, with an exercise price of $2.80 per share and an expiration date of 10/22/2035. Ownership of the derivative security is listed as Direct.
The option vests in full upon the earlier of October 23, 2026 or the date of the issuer’s next annual meeting of stockholders, subject to the director’s continued service through that date. Following the reported transaction, the director beneficially owned 53,521 derivative securities.
FAQ
What is the current stock price of Q32 BIO (QTTB)?
What is the market cap of Q32 BIO (QTTB)?
